13 Mar 2019
PCR @ ACC 2019 Scientific Sessions
The Interventional Cardiology perspective!
Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2019 Scientific Sessions #ACC19.
Late breaking Trials
- PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients: Results of the PARTNER 3 Trial
- Journal Club Review: PARTNER 3 results published in the New England Journal of Medicine
- Cardio Poll: Will PARTNER 3 change your practice?
- Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality
- Analysis of the STS/TVT Registry: Outcomes of Transcatheter Aortic Valve Replacement with Balloon-Expandable Sapien3 Valve in Bicuspid Aortic Stenosis
- AUGUSTUS Trial: An Open-label, 2 x 2 Factorial, Randomized Trial to Evaluate the Safety of Apixaban versus Vitamin K Antagonist and Aspirin versus Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention: Primary Results of the AUGUSTUS Trial
- Journal Club Review: AUGUSTUS results published in the New England Journal of Medicine
- SAFARI-STEMI: The Safety and Efficacy of Femoral Access versus Radial Access for Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction
- COACT Trial: Coronary Angiography after Cardiac Arrest without ST-Segment Elevation
- Journal Club Review: COACT results published in the New England Journal of Medicine
- STOPDAPT-2 Trial: One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy with Clopidogrel After Drug-Eluting Stent Implantation
- SMART-CHOICE: P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy in Patients Undergoing Implantation of Coronary Drug-eluting Stents
Mirvat Al Asnag, KFAFH King Fahad Armed Forces Hospital, Saudi Arabia, and Francesco Costa, University of Messina, Spain, provided their take on what was new and what was hot and provided you with condensed take-home messages from this congress.
- Read about the first day at ACC.19 and the early release of PARTNER 3 and the Evolut Low Risk Trials
- Read about day 2 at ACC.19 and the primary results of the AUGUSTUS Trial
- Find out more about the hot discussions and debates on the third and final day at ACC.19
